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Cannabis is reported to be remarkably effective for the relief of otherwise intractable pain. However, the
bases for pain relief afforded by this psychotropic agent are debatable. Nonetheless, the frontal-limbic dis-
tribution of cannabinoid receptors in the brain suggests that cannabis may target preferentially the affec-
tive qualities of pain. This central mechanism of action may be relevant to cannabinoid analgesia in
humans, but has yet to be demonstrated. Here, we employed functional magnetic resonance imaging to
investigate the effects of delta-9-tetrahydrocannabinol (THC), a naturally occurring cannabinoid, on brain
activity related to cutaneous ongoing pain and hyperalgesia that were temporarily induced by capsaicin in
healthy volunteers. On average, THC reduced the reported unpleasantness, but not the intensity of ongoing
pain and hyperalgesia: the speciﬁc analgesic effect on hyperalgesia was substantiated by diminished activ-
ity in the anteriormid cingulate cortex. In individuals, the drug-induced reduction in the unpleasantness of
hyperalgesia was positively correlated with right amygdala activity. THC also reduced functional connec-
tivity between the amygdala and primary sensorimotor areas during the ongoing-pain state. Critically, the
reduction in sensory-limbic functional connectivity was positively correlated with the difference in drug
effects on the unpleasantness and the intensity of ongoing pain. Peripheral mechanisms alone cannot
account for the dissociative effects of THC on the pain that was observed. Instead, the data reveal that
amygdala activity contributes to interindividual response to cannabinoid analgesia, and suggest that dis-
sociative effects of THC in the brain are relevant to pain relief in humans.
 2012 International Association for the Study of Pain. Published by Elsevier B.V.
Open access under CC BY license.1. Introduction
Delta-9-tetrahydrocannabinol (THC), a partial cannabinoid-1
(CB-1) receptor agonist, can relieve chronic pain that is often refrac-
tory to conventional analgesics [4]. The neural bases of such pain re-
lief remain unclear in humans, even though peripheral and central
mechanisms for cannabinoid analgesia have been demonstrated in
other species [39]. However, recent evidence reveals that CB-1
receptors densely populate frontal-limbic compared to somatosen-
sory areas in the human cortex [8,13,21]. This distribution ofUniversity of Oxford, John
865 222724; fax: +44 0 1865
tudy of Pain. Published by ElsevieCB-1 receptors in the brain suggests that THC may target the affec-
tive qualities of pain speciﬁcally, given that the affective-motiva-
tional and sensory aspects of pain are known to be separable
functions of frontal-limbic and somatosensory cortices, respec-
tively [2,6,47]. Of the limbic areas, data from preclinical studies
clearly demonstrate that ablation or inactivation of the amygdalae
attenuate markedly analgesia afforded by systemic CB-1 agonists
[42,43], which suggests that the amygdalae contribute signiﬁcantly
to cannabinoid analgesia.
We therefore hypothesised that the effect of THC on the affec-
tive qualities of pain in humans depends signiﬁcantly on how the
drug inﬂuences the functional activity of the amygdala. Since pre-
clinical studies have shown that the cannabinoids are more potent
in hyperalgesic states [28,40], we examined the effect of THC on
ongoing pain and hyperalgesia that is induced by capsaicin
sensitisation [34].r B.V. Open access under CC BY license.
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154 (2013) 124–134 125Capsaicin is an alkaloid derived from the chilli pepper. When
applied topically, capsaicin produces ongoing burning pain as a re-
sult of peripheral sensitisation at the site of application [45]. In
skin areas surrounding the site of capsaicin application, secondary
punctate hyperalgesia occurs, which results from central sensiti-
sation and is characterised by increased pain when normal tissue
is mechanically stimulated [38,70]. Healthy cannabis-naive
subjects volunteered for the randomised, double-blind, placebo-
controlled, 2-way drug crossover study. The effects of THC (single
dose) on the reported intensity and unpleasantness of capsaicin-
induced pain and hyperalgesia were determined in individuals.
Functional magnetic resonance imaging (fMRI) was used to inves-
tigate the extent to which the amygdalae explained the effects of
THC on ongoing pain and hyperalgesia in individuals.2. Methods
2.1. Subjects
Fifteen healthy, right-handed, cannabis-naïve men aged 24 to
34 years volunteered for the study. Women were excluded as the
experimental drug study lasts about 4–6 weeks, and there is clear
evidence for the potentially confounding effects of menstruation-
related hormone ﬂuctuations on pain in that month-long test per-
iod [59]. All subjects gave written informed consent and were
familiarised with experimental procedures. The Mid and South
Buckinghamshire local research ethics committee approved the
study (LREC 06/Q1607/24).
Prior to entering the study, these subjects were screened using
inclusion and exclusion criteria (Table 1). Data from 2 subjects
were excluded despite negative recreational drug urinalysis be-
cause further interview during the course of the study revealed
prior use of cannabis. One subject experienced drug-induced para-
noia, which rendered him claustrophobic, and was excluded from
the study because he could not undergo fMRI. His symptoms re-
solved completely over 24 hours and he remained well on fol-
low-up at a year, with no further psychiatric symptoms.
2.2. Study design
The study was randomised, double blind, and placebo con-
trolled. Each subject underwent 4 separate study sessions in a 2-
by-2 factorial design. The factors were drug (15 mg THC or placebo
taken orally; The Specials Laboratory, Northumberland, UK) and
state (normal or capsaicin-induced sensitisation).
The sessions were balanced for order. To minimise wash-over
effects related to THC or topical capsaicin application, the sessions
were separated by at least a week and the active treatments for
each study factor were administered on alternate sessions. Before
each session, subjects fasted for 8 hours and abstained from caf-
feine and alcohol. Prior to drug ingestion (ie, baseline), subjects
completed a simple visual-motor reaction time task (programmed
using Delphi) [12] and provided a urine sample for drug screen
(Multi-Drug Dip Card, Quantum Diagnostics, Waltham Abbey,
UK). Subjects rested in a dedicated room for 2 hours post drug
ingestion, after which the area for topical cream application and
punctate mechanical stimulation was deﬁned. A horizontal line
was drawn over the skin on the anteromedial aspect of the right
leg, 12–15 cm proximal to the medial malleolus. Two millilitres
of 1% topical capsaicin (Propharma, Horsham, UK) or placebo
cream was applied immediately above the line and occluded with
clear ﬁlm dressing (Tegaderm™, 3M Health Care, Neuss, Germany).
The cream remained on the skin until the end of the fMRI session.
The area, 4  4 cm, 1 cm below the horizontal line, was designated
for punctate mechanical stimulation during fMRI.Three hours post drug ingestion, fMRI was performed. The sub-
jects repeated the simple reaction time task 3.5 hours post drug
ingestion. Reaction time data from one subject was unavailable be-
cause of equipment failure. A 10-mL venous blood sample was
then obtained for gas chromatography-mass spectrometry assay
of plasma cannabinoid concentrations (ABS Laboratories, Hertford-
shire, UK).
2.3. fMRI scanning and stimulation paradigm
Functional imaging data were acquired with a 3 Tesla human
MRI system (1 m bore; Oxford Magnet Technology, Oxford, UK)
using a transmit-receive birdcage radiofrequency coil and a high-
performance reduced-bore gradient coil (Magnex SGRAD MK III,
Oxford, UK) for signal detection. The T2⁄-sensitive gradient echo-
planar-imaging sequence with the following parameters was used:
3-second repetition time, 30-ms echo time, 41 contiguous 3-mm-
thick slices, ﬁeld of view 192  192 mm, matrix 64  64 pixels,
500 volumes. The ﬁrst 4 volumes were discarded to permit equili-
bration of the blood-oxygen-level-dependent (BOLD) signal. Field
maps were obtained using a symmetric-asymmetric spin-echo se-
quence (echo time 20 ms, 2.5 ms dwell time, ﬁeld of view, and ma-
trix identical to echo planar imaging). A T1-weighted structural
image (1 mm3 voxel) was acquired to facilitate registration of
T2⁄-weighted images to standard stereotactic space (Montreal
Neurological Institute [MNI] 152 template).
Once the subject was comfortably supine in the magnet bore, a
single mean arterial pressure cuff measurement was obtained, and
continuous monitoring of pulse rate, pulse oximetry (SpO2), end-
tidal CO2 partial pressures (PETCO2) (9500 Multigas Monitor,
Wardray Premise, Surrey, UK) via nasal cannulae (Salter Labs, Arvin
CA, USA), respiratory rate (RR), and chest excursions (Piezo
Respiratory Belt Transducer, ADInstruments, Oxfordshire, UK)
commenced. These on-line measurements helped ensure subject
safety and provided cardiorespiratory data that were employed
for several purposes. First, to correct for interregional correlations
related to cardiorespiration (heart-rate and breathing ﬂuctuations)
during the analyses of functional connectivity. Second, to exclude
any confound on baseline BOLD signal related to hypoxemia
(decreased SpO2), or hypercarbia (increased CO2) related to
excessive sedation caused by THC.
Just prior to the functional scans, the subject rated the intensity
and unpleasantness of ongoing pain. The sequence of events during
the functional scans were as follows: a 5-minute period, during
which the subject performed no overt task but remained awake
with eyes closed; a 30-second period that commenced when the
subject was given a tactile cue (a tap on the leg) to rate the ongoing
pain; a 15-minute period, during which the subject was instructed
to direct attention, with eyes closed, to the punctate mechanical
stimuli that were applied to the designated area on the right leg;
a 1-minute period when the subject was again cued to rate the
ongoing and provoked pain; ﬁnally, the subject viewed 5 30-sec-
ond blocks of a black-and-white checkerboard ﬂickering at 2 Hz
that alternated with 5 30-second blocks of stationary ﬁxation.
Punctate stimulation was applied using a handheld mechanical
probe (ﬂat tipped, 200 lm diameter) calibrated to deliver 512 mN
force [52]. Twenty-one stimuli, each lasting 1 second, were deliv-
ered. The interstimulus interval was randomly jittered (10–40 sec-
onds) to allow higher effective sampling of the BOLD signal
following punctate stimulation.
Subjects rated the intensity and unpleasantness of ongoing and
provoked pain using an electronic MR-compatible visual analogue
scale (VAS) with visual feedback projected onto a screen visible
through periscope goggles (left anchor: not at all; right anchor:
intolerable). The word ‘‘intolerable’’ on the right anchor signiﬁed
the ethical limit of pain that can be induced, beyond which the
Table 1
Study inclusion, exclusion, and discontinuation criteria.
Inclusion criteria
1. Male subjects
2. Age between 18 and 50 years
3. Body weight between 60 and 100 kg and within the normal range for height (assessed by Quetelet index), normal range 18–24 kg m2
4. Cannabis naïve
5. Nonsmokers
Exclusion criteria
1. Evidence of any clinically signiﬁcant disease on direct questioning and physical examination with particular attention to cardiovascular disorder, chronic pain,
psychiatric or neurological condition
2. History of clinically signiﬁcant drug allergies (including allergy to chilli peppers)
3. Report of taking, or having taken, any prescribed or over-the-counter drug in the week prior to the start of the study
4. Received any experimental drug in the last 3 months prior to the ﬁrst dosing day of the study
5. Habit of drinking more than 28 units of alcohol per week
6. Evidence of past or current recreational drug use on direct questioning; or positive drug urinalysis on prestudy screening
7. Contraindication to fMRI
Discontinuation criteria
1. Ineligibility, either arising during the study or retrospectively having been overlooked during screening
2. Subject noncompliance with study requirements (for example, a positive urinalysis prior to any of the study sessions)
3. Any adverse event, which results in the subject being unable to continue to comply with study procedures
fMRI, functional magnetic resonance imaging.
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pain was deﬁned as the degree of burning and sharp sensation,
respectively. The unpleasantness of ongoing and provoked pain
was deﬁned in terms of how much the sensation bothered the sub-
ject. The subject was allowed 15 seconds to consider each scale and
was speciﬁcally instructed to rate the overall experience, rather
than focus on discrete provoked sensations.
2.4. Analyses of psychophysical and cardiorespiratory data
Statistical analyses were performed using SPSS 15.0 for Win-
dows (SPSS Inc, Chicago, IL, USA). Repeated-measure 2  2 analysis
of variance, with Greenhouse-Geisser correction for nonsphericity
of data, was employed to ascertain signiﬁcant effects of drug
(THC or placebo) and state (normal or capsaicin sensitised) on
the following parameters: intensity and unpleasantness of ongoing
as well as provoked pain. Each of the 4 pain parameters was calcu-
lated as the mean of the 3 VAS ratings reported during fMRI scan.
The repeated-measure analysis of variance was similarly employed
to ascertain signiﬁcant drug and state effects on simple reaction
time. The effect of the drug on reaction time was measured as
the difference between postdrug and baseline values. Bonferroni
corrections were employed during post hoc tests. The effects of
drug and state on the mean pulse rate, RR, SpO2, and PETCO2 were
similarly examined. A paired t test was used to compare plasma
concentrations of THC and 11-hydroxy THC obtained from blood
sampling 4 hours post dose.
2.5. Analyses of imaging data
fMRI analyses were performed using FEAT (FMRIB Expert Anal-
ysis Tool) Version 5.92, part of FSL (FMRIB’s Software Library,
http://www.fmrib.ox.ac.uk/fsl).
Preprocessing included motion correction [30]; removal of non-
brain structures [58]; spatial smoothing using a Gaussian kernel of
full width at half maximum 8mm to reduce intersubject gyral
differences; mean-based intensity normalisation of each 4-
dimensional dataset by the same factor; high pass temporal ﬁlter-
ing (Gaussian weighted least-squares straight line ﬁtting, r =
100 s); and physiological noise correction (cardiac and respiratory)
using modiﬁed RETROICOR [7,22].
Once preprocessing was complete, the single time series of 496
volumes was divided into 3 time series. The ﬁrst 126 volumes
comprised the time series for the ‘‘no-task’’ period. The time seriescorresponding to punctate and visual stimulation comprised 215
and 106 volumes, respectively. Volumes corresponding to periods
when subjects used the VAS were discarded.
Input stimulus functions, deﬁned for the punctate and visual
stimuli, were convolved with the canonical hemodynamic re-
sponse function (mean lag 6 seconds, full width at half maximum
6 seconds) to yield regressors of interest for the general linear
model. Individual time-series statistical analysis was carried out
using FILM (FMRIB’s Improved Linear Model) with local autocorre-
lation correction [66]. Motion parameters acquired from prepro-
cessing were included as nuisance regressors. First-level
statistical maps were generated for BOLD activation associated
with punctate and visual stimulation. The functional images were
ﬁeld-map corrected to reduce B0 distortion in the orbital-frontal
and temporal regions [29]. Image registration to high-resolution
structural and standard MNI-space images was then performed
for the purposes of group analyses [30,31].
2.5.1. Whole brain analyses
The aim of the whole brain analyses was to identify where THC
affected brain activity that was associated with capsaicin-induced
hyperalgesia. Group mean maps were generated using FLAME
(FMRIB’s Local Analysis of Mixed Effects), a random-effects analysis
[5,65]. A repeated-measures factorial analysis was used to generate
z (Gaussianised T/F) statistic maps of the main (drug, state) and
interaction (drug  state) effects on BOLD responses to punctate
stimulation. The cluster-based correction formultiple voxel compar-
isons (z > 2.0, P < 0.05) was then applied to thewhole brainmap [17].
2.5.2. Region of interest analyses
Region of interest (ROI) analyses were carried out to test our a
priori hypothesis that amygdala activity contributes signiﬁcantly
to the analgesic effects of THC in humans, and to exclude global ef-
fects of THC on BOLD responses [64].
All anatomical ROIs were deﬁned using the Harvard Oxford Corti-
cal and Subcortical Structural Atlas (http://www.fmrib.ox.ac.uk/fsl/
data/atlas-descriptions.html), which is a probabilistic population-
based atlas. Only voxels estimated at >50% of probability of being
in the structure were included in the ROI. The approach ensured a
reproducible and conservative deﬁnition for the amygdala and intra-
calcarine (visual) anatomical ROI. The threshold of signiﬁcance for
small volume correction [67] for all ROIs was set to P < 0.01.
The cluster of voxels within the amygdala anatomical ROI on
which THC had a signiﬁcant main effect during hyperalgesia was
M.C. Lee et al. / PAIN
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nal was extracted and averaged from signiﬁcant voxels within
the functional ROI using Featquery (http://www.fmrib.ox.ac.uk/
fsl/feat5/featquery.html) for every subject and condition. Two-
tailed signiﬁcance testing of the Pearson’s r was then used to
examine correlations between the drug-induced change in amyg-
dala reactivity to noxious stimulation and the drug-induced
change in the reduction of pain ratings.
2.5.3. Interaction effects of THC and capsaicin on the functional
connectivity of the amygdala
Functional connectivity (Fc) is a measure of correlated BOLD
activity between the reference and target region(s). For this study,
the reference ROI comprised the amygdala cluster of voxels on
which THC had a signiﬁcant main effect during hyperalgesia (ie,
the functional ROI).
Converging lines of evidence suggest that Fc reﬂects anatomi-
cally and functionally relevant coupling within neuronal circuitries
[50], with the caveat that a ﬁnding of ‘‘functional connection’’ does
not prove structural or causal connections, as Fc measures are cor-
relative in nature. Analyses of Fc in this study were achieved with
methods developed to identify psychophysiological interactions
[16]. The factorial experimental design employed in this study al-
lowed isolation of Fc that relates speciﬁcally to the effects of THC
on ongoing pain [23].
The ﬁrst 126 volumes of the fMRI scan comprised the time series
for the ‘‘no-task’’ period, during which the subjects performed no
overt task except to stay awake with eyes closed whilst experienc-
ing the effects of drug and capsaicin sensitisation. These time series
were used for the Fc analyses. BOLD signals from all voxels compris-
ing the amygdala functional ROI were extracted and averaged to
produce the regressor for the general linear model of BOLD activity
during the ‘‘no-task’’ period. Preprocessing of the fMRI time series
was as described above. Motion parameters acquired from prepro-
cessing were included as nuisance regressors. The ﬁrst-level analy-
ses of the general linear model served to generate whole-brain
images of the functional connections of the right amygdala ROI
for every subject and session. As before, the images were corrected
for B0 distortion [29] before registration to high-resolution struc-
tural and standard MNI-space images was performed [30,31]. The
transformed images were subsequently subjected to the group-
level random-effects analysis [5,65]. A repeated-measures factorial
analysis was used to generate z (Gaussianised T/F) statistical maps
to represent the interaction effect (drug  state) on BOLD responses
on the Fc of the amygdala ROI. For consistency, the cluster-based
correction for multiple voxel comparisons (z > 2.0, P < 0.05) was
again applied to the whole brain maps [17].
3. Results
The data reported here are from12healthy, right-handed, canna-
bis-naïve men aged 24 to 34 years. All subjects underwent 4 exper-
imental sessions in the crossover study, where THC or placebo (PLC)
was administered on normal or capsaicin-sensitised skin. The plas-
ma concentrations of THC and 11-hydroxy THC obtained fromblood
sampling 4 hours post dosewere not signiﬁcantly different (paired t
test; P > 0.1) between control and capsaicin conditions (Fig. 1).
3.1. Behavioral and physiological effects of THC
Capsaicin induced ongoing burning pain [main effect: intensity,
P < 0.001, F(1,11) = 38.0] and heightened pain provoked by noxious
punctate stimuli [main effect: intensity, P < 0.001, F(1,11) = 26.5]
(Fig. 2, Table 2). Compared to PLC, THC did not signiﬁcantly alter
the perceived intensity of ongoing or mechanically provoked pain.However, the cannabinoid signiﬁcantly reduced the perceived
unpleasantness of both ongoing and provoked pain after capsaicin
sensitisation (2-tailed paired t tests, Bonferroni adjustment:
P < 0.05).
Compared to PLC, THC slowed the response to a simple visual-
motor reaction-time task [main effect: P < 0.05, F(1,10) = 5.9],
which was consistent with its sedative effects. Capsaicin did not af-
fect reaction times (Fig. 3, Table 2).
3.2. Effects of THC on brain activity related to capsaicin-induced
hyperalgesia
Capsaicin sensitisation increased BOLD activity during pro-
voked pain in the thalami, as well as the anterior cingulate cortex
(ACC; main effect of capsaicin, z > 2.0; cluster-based correction
P < 0.05) (Fig. 4). Please refer to Table 3 for the local maxima of
activations in other brain regions for the effects related to capsai-
cin-induced punctate hyperalgesia that did not survive cluster-
based threshold (P < 0.05) for multiple comparisons. However, a
signiﬁcant interaction between capsaicin and THC on BOLD activa-
tion occurred in the ACC only (z > 2.0; cluster-based correction
P < 0.05). Activation in the ACC related to capsaicin-induced hyper-
algesia was decreased with THC compared to PLC. The extent to
which this ﬁnding corroborates the effect of THC on the unpleas-
antness of capsaicin-induced hyperalgesia is discussed later.
Next, we focused on the amygdalae as ROIs, given our hypothe-
sis regarding their role in cannabinoid analgesia [42,43]. We found
that themain effect of THCwas a signiﬁcant increase in right amyg-
dala BOLD response to noxious stimulation (small volume correc-
tion, P < 0.01) (Fig. 5). In order to ascertain whether the inﬂuence
of THC on right amygdala BOLD response was relevant to the effect
of THC on the unpleasantness of capsaicin-induced hyperalgesia,
we examined the correlation between the BOLD response and the
effect of the drug on the unpleasantness of hyperalgesia in individ-
uals.We found a signiﬁcantly positive correlation (P < 0.01, r = 0.72)
between the effect of THC on the right amygdala BOLD response
and the analgesic effect of THC (Fig. 5), which was deﬁned as the
reduction in the unpleasantness of capsaicin-induced hyperalgesia.
In contrast, there were no signiﬁcant effects of THC or capsaicin
onBOLD responses related to visual stimulation in the intracalcarine
anatomical-region ROI. The lack of drug effect on the visual-related
BOLD responses activity concurs with results from a previous fMRI
study [46] and suggests a speciﬁc effect of THC on BOLD responses
that are related to the neural processing of noxious inputs.
We further conﬁrmed that there was no signiﬁcant inﬂuence of
either THC or capsaicin on PETCO2, RR, or SpO2 because these
parameters can inﬂuence BOLD activity directly. THC increased
pulse rate [main effect: P < 0.05, F(1,11) = 5.0], as did topical capsa-
icin [main effect: P < 0.05, F(1,11) = 6.2] (Fig. 3, Table 2). However,
the drug effects on pulse rate were slight (3–5 beats per minute)
and did not exhibit any interaction effects with capsaicin that
could account for our observed effects of THC on the BOLD re-
sponse during capsaicin-induced sensitisation.
3.3. Effects of THC and capsaicin on the Fc of the right amygdala
Having isolated the region in the right amygdala involved in the
effect of THC on capsaicin-induced hyperalgesia, we proceeded to
identify the functional connections underlying the analgesic effect
on capsaicin-induced ongoing pain. We found that THC signiﬁ-
cantly reduced (z > 2.0; cluster-based correction P < 0.05) Fc be-
tween the right amygdala and the primary sensorimotor cortex
during the ongoing pain state (Fig. 6, top images). Because THC sig-
niﬁcantly suppressed BOLD responses within the ACC during punc-
tate hyperalgesia (Fig. 4), we also examined whether Fc between
control capsaicin 
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Fig. 1. The plasma concentrations of delta-9-tetrahydrocannabinol (THC) and its
active metabolite, 11 hydroxy (OH)-THC. Blood was sampled for plasma concen-
trations about 3.5 hours after THC was given. There were no signiﬁcant differences
(2-tailed paired t test, P > 0.05). Error bars represent SEM. Black and clear bars
represent capsaicin and control sessions respectively. n.s., nonsigniﬁcant.
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ongoing pain. The results suggest that THC increased Fc between
the right amygdala and ACC, but did not survive voxel-based
(small-volume) correction (P < 0.01) [67].
We then explored to what extent the decreased Fc between the
amygdala and sensorimotor cortex induced by THC was related to
the psychophysical effects of the drug on ongoing pain. In the pres-
ent study, THC had divergent effects on the intensity and unpleas-
antness of ongoing pain. Individuals who experience a reduction in
the unpleasantness of ongoing pain may experience either similar
or opposite effects on the intensity of pain (Fig. 6, bottom-left
graph). This dissociative effect of THC on pain was quantiﬁed byFig. 2. Capsaicin induced signiﬁcant ongoing burning pain and caused an increase in pain
(THC) signiﬁcantly reduced the effect of capsaicin on the unpleasantness, but not the i
⁄P < 0.05). Error bars represent SEM. Black and clear bars represent THC and placebo, rethe absolute difference between the effects of the drug on the
intensity and unpleasantness of ongoing pain (Fig. 6, bottom left).
We investigated whether the dissociative effects of THC on the
experience of pain might be explained by altered Fc between the
amygdala and primary somatosensory cortex (S1) speciﬁcally.
The sensation of pain was induced by application of capsaicin in
the right lower limb. Hence, the S1 ROI comprised an 8-mm sphere
centred on the voxel with the group peak interaction (state  drug)
effect (MNI coordinates 36, 34, 62; z = 4.1) within the left post-
central gyrus (as deﬁned by the Harvard Oxford Cortical Structural
Atlas (http://www.fmrib.ox.ac.uk/fsl/data/atlas-descriptions.html).
Consistent with other ROIs deﬁned using this approach in the
study, only voxels estimated at >50% of probability of being in
the structure were included in the ROI.
The parameter estimates for the interaction effect (drug  state)
that represents the reduction of Fc between the right amygdala and
primary somatosensory area (S1) of THC during ongoing pain were
then derived for each individual (http://www.fmrib.ox.ac.uk/fsl/
feat5/featquery.html). We found that the reduction of sensory-lim-
bic Fc by THC was positively correlated (Pearson’s r = 0.64, P < 0.05)
with the divergent effects of the drug on the intensity and unpleas-
antness of ongoing pain (Fig. 6, bottom-right graph). In other
words, the greater the effects of THC on one aspect of pain relative
to the other, the greater the loss of Fc between the amygdala and
S1 (primary somatosensory area).
4. Discussion
Previous psychophysical studies have revealed inconsistent re-
sults regarding the effects of THC on pain and hyperalgesia
[1,35,56,62]. Such studies employed psychophysical indices that
focused on the sensory aspects of pain, and consistent with theseprovoked by punctate stimuli. Compared to placebo, delta-9-tetrahydrocannabinol
ntensity of provoked and ongoing pain (Bonferroni adjusted post hoc paired t test,
spectively. VAS, visual analogue scale.
Table 2
Repeated-measures 2  2 ANOVA (Greenhouse-Geisser correction) for the effects of drug (placebo or THC) and state (normal or capsaicin sensitised) on pain ratings, reaction
time, and cardiorespiratory variables.
df (hypothesis, error) MS F P-value
Ongoing pain
Intensity
Drug (main effect) 1, 11 0.52 0.61 0.452
State (main effect) 1, 11 173.97 37.91 < 0.001
Drug x State (interaction) 1, 11 0.56 0.935 0.354
Unpleasantness
Drug (main effect) 1, 11 2.32 7.567 0.019
State (main effect) 1, 11 144.94 24.88 < 0.001
Drug x State (interaction) 1, 11 2.8 11.11 0.007
Provoked pain
Intensity
Drug (main effect) 1, 11 4.56 3.34 0.095
State (main effect) 1, 11 128.5 26.5 < 0.001
Drug x State (interaction) 1, 11 0.3 0.3 0.595
Unpleasantness
Drug (main effect) 1, 11 1.3 0.931 0.355
State (main effect) 1, 11 104.73 24.05 < 0.001
Drug x State (interaction) 1, 11 6.68 5.59 0.03
Visual motor reaction time
Drug (main effect) 1, 10a 0.01095 5.863 0.036
State (main effect) 1, 10a 0.001131 1.312 0.2787
Drug x State (interaction) 1, 10a 0.001677 2.219 0.1672
Pulse rate
Drug (main effect) 1, 11 172.1 4.912 0.0487
State (main effect) 1, 11 81.39 6.246 0.0296
Drug x State (interaction) 1, 11 0.0003 <<<1 0.9973
Respiratory rate
Drug (main effect) 1, 11 1.647 0.7644 0.4006
State (main effect) 1, 11 1.365 0.1830 0.6711
Drug x State (interaction) 1, 11 3.321 0.6351 0.4424
End-tidal carbon dioxide
Drug (main effect) 1, 11 18.40 3.454 0.09
State (main effect) 1, 11 9.541 1.711 0.2175
Drug x State (interaction) 1, 11 2.347 0.4247 0.5284
Pulse oxygen saturation
Drug (main effect) 1, 11 2.093 0.9463 0.336
State (main effect) 1, 11 0.2765 0.1250 0.7253
Drug x State (interaction) 1, 11 2.093 0.9463 0.3360
ANOVA, analysis of variance; THC, delta-9-tetrahydrocannabinol; MS, mean square; df, degrees of freedom.
a Data unavailable for 1 subject because of equipment failure.
0.3
0.4
0.5
50
60
70
80
Fig. 3. Delta-9-tetrahydrocannabinol (THC) slowed reaction times (main effect, ⁄P < 0.05) and increased resting pulse rate slightly (main effect, ⁄P < 0.05). There was no
signiﬁcant effect of capsaicin on reaction times. However, there was a slight increase in resting pulse rate during capsaicin-induced sensitisation compared to control (main
effect, ⁄P < 0.05). Error bars represent SEM. Black and clear bars represent THC and placebo, respectively.
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pain intensity (sensory aspect) of capsaicin-induced pain or hyper-
algesia. Instead, we found that THC relieved speciﬁcally the per-
ceived unpleasantness of pain and hyperalgesia induced by
capsaicin. The divergent effect of THC on sensory and affective as-
pects of somatosensation has also been reported by Libman and
Stern, who observed that THC can lower sensory thresholds to
innocuous stimuli whilst increasing pain tolerance [41]. THC doeshave sedative effects [12], which was evidenced by a generalised
increase in visual-motor reaction times in our study. Importantly,
the analgesic effect of THC was evident only when pain and hyper-
algesia were induced by capsaicin. Thus, general sedation does not
account for the analgesic effect of THC that was reported by our
subjects.
The dissociative analgesic effects of THC on experimentally in-
duced pain in this study were further corroborated by fMRI data.
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Fig. 4. The main effect of capsaicin, indicated in red, was to increase blood-oxygen-level-dependent (BOLD) activation in the anterior cingulate cortex (ACC) (Montreal
Neurological Institute [MNI] peak coordinates 6, 20, 30; z score = 3.8) and thalami (left thalamus: MNI peak coordinates 12, 26, 16; z score = 3.2, right thalamus: MNI
peak coordinates 10, 22, 14; z score = 3.6). The effect of interaction between delta-9-tetrahydrocannabinol (THC) and capsaicin, indicated in blue, was signiﬁcant in the ACC
only (MNI peak coordinates 8, 22, 28; z score = 4.6). The graphs clarify the effects of THC and placebo (PLC) on capsaicin-induced BOLD responses. Capsaicin-induced BOLD
response was calculated as the difference (cap  con) in percentage BOLD signal change between capsaicin (cap) and control (con) sessions. Compared to PLC, THC decreased
the BOLD response in the ACC related to hyperalgesia (top graph). In contrast, activation within thalami related to hyperalgesia did not differ signiﬁcantly. Coloured bars
denote range of z scores. Clear and black bars represented PLC and THC, respectively. Error bars represent SEM.
Table 3
Main effect of THC (z score >2.0) on BOLD activations in regions known to be involved in hyperalgesia that did not survive cluster-based correction for multiple comparisons
(P < 0.05).
Region deﬁned by the Harvard-Oxford structural probabilistic atlas (P > 0.5) L: left; R: right MNI coordinate of peak voxel Voxel level
x y z z-score
Brainstem (periaqueductal gray) 6 38 24 3.4
Cerebellum 16 38 24 4.12
L insula 36 16 12 3.65
R insula 38 4 4 2.12
L primary somatosensory cortex 50 20 42 2.51
L amygdala 26 10 14 2.58
R amygdala 26 0 14 3.23
L hippocampus 18 14 16 2.85
R hippocampus 24 28 8 2.89
L putamen 26 0 8 2.3
R putamen 24 4 8 4.7
L caudate 16 6 20 2.12
THC, delta-9-tetrahydrocannabinol; BOLD, blood-oxygen-level-dependent; MNI = Montreal Neurological Institute.
The regions were deﬁned using the Harvard-Oxford structural probabilistic atlas. The MNI coordinates of local maxima for each region are reported.
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Fig. 5. Region-of-interest analyses revealed that the main effect of delta-9-tetrahydrocannabinol (THC) was to signiﬁcantly increase blood-oxygen-level-dependent (BOLD)
response within the right amygdala (37 signiﬁcantly activated voxels; Montreal Neurological Institute [MNI] coordinates of peak voxel 26, 0, 14; z score = 3.23). The
coloured bars represent the range of z scores. MNI coordinates are indicated at the bottom right of each slice. The graph shows that in individuals, analgesic effect of THC on
the unpleasantness of hyperalgesia was positively and signiﬁcantly correlated with the effect of THC compared to placebo (PLC) on capsaicin-induced responses in the right
amygdala (P < 0.01, r = 0.72). VAS, visual analogue scale.
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to hyperalgesia within the ACC but did not signiﬁcantly reduce
activation in the posterior thalami (Fig. 4). Only a subset of all re-
gions known to be involved in punctate hyperalgesia was signiﬁ-
cantly activated in this study when compared to 2 of our
previous studies [38,69]. This may relate to the presence of ongo-
ing pain induced by highly concentrated capsaicin (1%) that was
maintained throughout scanning and was not present in those pre-
vious studies. Ongoing pain induced by capsaicin itself is associ-
ated with increased cerebral blood ﬂow and hence, elevates
baseline BOLD signal in brain regions associated with punctate
hyperalgesia [27]. Experimental data have revealed that the abso-
lute increase in BOLD signal evoked by a stimulus is constant
regardless of the baseline signal [26,57]. Increases in the baseline
BOLD signal can be associated with a relative decrease of stimu-
lus-evoked response compared to the baseline. This implies that
areas where the increase in activity related to punctate hyperalge-
sia is less marked to begin with may not exhibit signiﬁcant re-
sponses when the baseline signal is increased in the presence of
ongoing pain. Hence, BOLD-fMRI assay sensitivity in our study
may be reduced for the detection of responses related to hyperal-gesia with strong ongoing pain. The robustness of BOLD responses
in the anterior cingulate and thalami to punctate stimulation in the
presence of ongoing pain suggests their signiﬁcant involvement
during capsaicin-induced hyperalgesia, which is supported by pre-
vious data of capsaicin-induced hyperalgesia (refer to Supplemen-
tary Table in [38]).
Preclinical studies consistently demonstrate that ACC lesions re-
duce conditioned place avoidance but not withdrawal behaviour in
inﬂammatoryandneuropathic [10,19,33,37]painmodels, supporting
a role for that region in higher-order pain behaviour. Patients who
haveundergoneanterior cingulotomyfor the treatmentof intractable
pain [25,63,68] have relatively intact sensory perception of noxious
stimuli, but their affective responses to the stimulus are markedly
attenuated [15]. In further support of the role of the ACC for the affec-
tive-motivational aspects of pain, Rainville and colleagues have
shown that the limbic structure ismore active when the unpleasant-
ness of pain is aggravated by hypnotic suggestion [49]. Notably, the
ACC regionactivated in their study ispreciselywhereTHCsuppressed
activation related to hyperalgesia in our study.
Based on recent cytoarchitectural studies, Vogt suggests that
the ACC may be subdivided into the anterior and mid cingulate
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Fig. 6. (Top) Delta-9-tetrahydrocannabinol (THC) signiﬁcantly reduced the right amygdala and primary sensorimotor functional connectivity (Fc) during capsaicin-induced
ongoing pain (z > 2.0; cluster-based correction). z-Scores indicating the degree to which THC reduced Fc are scaled in blue. Montreal Neurological Institute (MNI) coordinates
are indicated at the bottom right of each slice. (Bottom-left graph) The dissociate effect that THC has on the intensity (INT) and unpleasantness (UNPL) of capsaicin-induced
pain in each individual (represented by connecting lines). Negative visual analogue scale (VAS) units on the Y-axis indicate an analgesic effect. The dissociative effect of THC
on pain was calculated as the absolute difference of drug effects on the intensity and unpleasantness of ongoing pain, and is indicated in dashed red lines and bracket for an
individual. (Bottom-right graph) THC-induced reduction of sensory-limbic Fc was positively correlated with the dissociative effect of the drug on ongoing pain. The
interaction term for the drug effect on the sensory-limbic Fc associated with ongoing pain is drug [PLC-THC]  state [CAP-CON]. For each individual, parameter estimates for
the interaction effect were calculated for the left-S1 region of interest, which consisted of an 8-mm-diameter sphere centred on the group peak interaction (state  drug)
effect within the post-central gyrus (MNI coordinates 34, 36, 62). PLC, placebo; CAP, capsaicin-sensitised state; CON, control state.
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cingulate region in our study is identiﬁed as the anterior mid cin-
gulate cortex, which crucially, is a region that communicates ana-
tomically with the amygdala [3,20,61]. Preclinical studies clearly
demonstrate that ablation or inactivation of the amygdalae atten-
uate analgesia afforded by systemic CB-1 agonists [42,43]. These
data led us to speciﬁcally explore whether amygdala activity plays
a key role during cannabinoid analgesia in humans. In contrast to
the decreased ACC response during cannabinoid analgesia, the
main effect of THC was to increase amygdala response during nox-
ious stimulation. Importantly, the increase in capsaicin-induced
amygdala response and the analgesic effect of THC was positively
correlated, which indicates that amygdala activity contributes to
interindividual variation in analgesic drug response. Evidence from
rodent studies suggests that cannabinoid analgesia involves activa-
tion of the brainstem circuitry for the descending inhibition of
nociception via the amygdala [42,44]. However, our Fc analyses
did not reveal signiﬁcantly altered Fc between the amygdala and
brainstem during cannabinoid analgesia with this study design.
Instead, we found that THC signiﬁcantly reduced Fc between the
amygdala and a large portion of the primary sensorimotor area. Spe-
ciﬁcally, the reductionof Fc between theamygdala and the left S1 re-gion was positively correlated with the dissociative effects of the
drug on the reported intensity and unpleasantness of pain in the
right lower leg. For an unbiased analysis, the S1 ROI was centred
on the peak coordinates within the left postcentral gyrus, even
though they are unlikely to fall within the representation area of
the right leg. Direct anatomical connections between S1 and amy-
gdalae are sparse [55]. In contrast, ample clinical [15,48] and phys-
iological [18,24,36,49] evidence in humans supports the concept
that nociceptive information ascends in divergent parallel ascend-
ing pathways to sensory and limbic regions. A selective action of
THC on CB-1 receptor dense limbic pathway could explain parsimo-
niously the ﬁndings of reduced sensory-limbic Fc in the face of drug-
induced dissociative analgesia. However, the parallel model does
not account for how the separable dimensions of pain are normally
united in human consciousness [14], and THCmightwell disrupt the
integration of neural information between sensory and limbic re-
gions from which the experience we recognise as pain arises.
We found involvement of the right rather than the left amyg-
dala during cannabinoid analgesia. There are previous data that
can account for the lateralisation of cannabinoid effects on pain-
related amygdala activity. Several investigators have recently
demonstrated that inﬂammation-induced activation or plasticity
M.C. Lee et al. / PAIN

154 (2013) 124–134 133of the right amygdala is independent of the laterality of peripheral
inﬂammation, which attests to the right-hemispheric lateralisation
of amygdala function during pain [11,32]. The male gender in our
study may also contribute to the hemispheric lateralisation of drug
effect: highly salient stimuli are preferentially processed by the
right amygdala in men [9].
THC was administered systemically in our study. Consequently,
peripheral mechanisms for the observed effect of the cannabinoid
on capsaicin-induced hyperalgesia cannot be excluded [53]. How-
ever, peripheral or spinal mechanisms do not account adequately
for the divergent effects of THC on the sensory and affective as-
pects of pain that we observed in this study. Instead, our data dem-
onstrate that the effects of THC in the brain, characterised by
altered functional activities of the right amygdala, account for
the interindividual variation in analgesic efﬁcacy.
Cannabis has been reported to be remarkably effective for the
relief of otherwise intractable pain in patients [54]. However, the
bases of such pain relief afforded by this psychotropic agent are
debatable [51,54]. Our data reveal that speciﬁc effects of THC, the
psychotropic component of cannabis, on the amygdala contribute
to the analgesic effects of the drug reported by healthy volunteers.
Identifying patients who rely on similar central effects from canna-
bis-based medicines for pain relief remains challenging, but our
study indicates that the use of functional brain imaging for that
purpose merits further investigation.Conﬂict of interest statement
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